secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2026-08-05T20:14:24+00:00
Accession:  0001787306-26-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q2 net income $15M, revenue $129.9M (+59% YoY); raises FY guidance; CCO resigns
--------------------------------------------------------------------------------

- Q2 net product revenue $129.9M (+59% YoY, +23% QoQ); net income $15.0M ($0.11 EPS) vs net loss $15.9M in Q2 2025.
- Raised FY2026 net product sales guidance to $525M-$540M from $480M-$495M.
- FDA approved ZORYVE cream 0.3% for children aged 2+; sNDA accepted for ZORYVE cream 0.05% in infants (PDUFA Feb 23, 2027).
- CCO L. Todd Edwards resigns effective Aug 21; Robert Lisicki appointed interim CCO (base $555K, equity grants).
- Positive operating cash flow $12.6M; cash $238.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/0001787306-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/arqt-20260731.htm
  HTML page:      https://secwatch.observer/filing/0001787306-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer